Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Payables: 2018-2025

Historic Payables for Neurogene (NGNE) over the last 6 years, with Sep 2025 value amounting to $1.5 million.

  • Neurogene's Payables fell 8.31% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year increase of 6.34%. This contributed to the annual value of $1.3 million for FY2024, which is 48.54% down from last year.
  • Per Neurogene's latest filing, its Payables stood at $1.5 million for Q3 2025, which was down 25.05% from $2.1 million recorded in Q2 2025.
  • Neurogene's 5-year Payables high stood at $5.4 million for Q1 2023, and its period low was $1.3 million during Q4 2024.
  • In the last 3 years, Neurogene's Payables had a median value of $2.1 million in 2025 and averaged $2.5 million.
  • Its Payables has fluctuated over the past 5 years, first slumped by 71.92% in 2024, then surged by 101.25% in 2025.
  • Neurogene's Payables (Quarterly) stood at $2.6 million in 2023, then slumped by 48.54% to $1.3 million in 2024, then dropped by 8.31% to $1.5 million in 2025.
  • Its Payables was $1.5 million in Q3 2025, compared to $2.1 million in Q2 2025 and $3.1 million in Q1 2025.